Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-04-27 Investor Presentation
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Seneffe Manufacturing Facility - Shareholder Walkthrough 12 pages 12.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Telix Pharmaceuticals' global manufacturing strategy, focusing on the Seneffe facility in Europe. It includes descriptions of current and future manufacturing plans, strategic partnerships, facility specifications, regulatory compliance, and financial impact related to the facility acquisition and build-out costs. The content is structured with headings, bullet points, and images (omitted here), typical of a corporate presentation aimed at investors or stakeholders. There are no financial statements, audit opinions, voting results, or legal proceedings mentioned. The document length is 9663 characters, which is substantial and consistent with a presentation rather than a brief announcement or regulatory filing. The focus on strategy, operations, and financial implications without detailed financial data or regulatory compliance filings aligns best with an Investor Presentation (IP).
2020-04-27 English
Cover note to Seneffe Facility - Shareholder Walkthrough 1
Investor Presentation Classification · 90% confidence The document is a shareholder communication providing a walkthrough of a recently acquired manufacturing facility. It references a prior quarterly shareholder update call and provides operational details about the facility. The document is relatively short (2934 characters) and does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release, annual or interim report, or any formal regulatory filing. It is an informational update aimed at shareholders about a specific operational asset. This fits best under Investor Presentation (IP) as it focuses on company operations and strategic assets for investors, rather than formal financial reporting or regulatory announcements.
2020-04-27 English
Telix enters exclusive licence with Osaka University 2 pages 193.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals has entered into an exclusive license agreement with Osaka University for a novel radiochemistry technology. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. It is a corporate announcement about a licensing deal and research collaboration. The document length is 4541 characters, which is relatively short and consistent with a corporate announcement rather than a detailed report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial filing. It also does not fit into categories like M&A, Capital Update, or Legal Proceedings. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2020-04-26 English
Quarterly Shareholder Update 12 pages 1.0MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Telix Pharmaceuticals Limited Quarterly Shareholder Update' dated April 22, 2020. It contains detailed financial and operational information including cash runway, share price, market capitalization, key accomplishments, outlook, marketing authorization submissions, COVID-19 impact, and business continuity plans. It discusses quarterly sales data (Q1 2020), regulatory feedback, and clinical trial updates. The document is about a quarterly period and includes substantive financial data and analysis, not just an announcement or summary. It is not a full annual report, nor an earnings release with just highlights, but a comprehensive quarterly update with financial and operational details. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-21 English
Investor conference call - transcript of CEO presentation 8 pages 210.4KB
Call Transcript Classification · 100% confidence The document is a detailed transcript of a shareholder update call by Telix Pharmaceuticals Limited, dated 22 April 2020. It includes a CEO presentation discussing quarterly activities, regulatory submissions, clinical trial progress, sales updates, and the impact of COVID-19 on the business. The content is a full text transcript of a conference call, including slide references and detailed commentary on company operations and outlook. There is no indication that this is a brief announcement or a report publication notice; rather, it is a comprehensive call transcript. Therefore, the document fits the definition of a Call Transcript (CT).
2020-04-21 English
Appendix 4C and Activity Report March 2020 quarter 8 pages 516.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Activity Report and Sales Note to Accompany Appendix 4C' and includes detailed quarterly financial data, including cash flow statements, operating expenditures, investing and financing activities, and cash reserves. It references the quarter ended 31 March 2020, indicating it is a quarterly report. The presence of Appendix 4C, which is a standard Australian Securities Exchange (ASX) quarterly cash flow report, confirms this is a quarterly financial report. The document also includes operational updates, regulatory milestones, and commercial activities, which are typical in interim or quarterly reports. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.